Effect of PIK3CA mutation to anti-cancer drugs of breast cancer.

PIK3CA突变对乳腺癌抗癌药物的影响。

• 批准号: 21791266
• 负责人: HARA Fumikata
• 金额: $ 2.58万
• 依托单位: 国立病院機構四国がんセンター (2011)Department of Clinical Research, National Hospital Organization Shikoku Cancer Center (2009-2010)
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21791266/
• 关键词: 乳癌; 薬剤耐性; PIK3CA遺伝子変異; ドセタキセル; タモキシフェン; 癌; 遺伝子; 医療福祉; 臨床; 薬剤反応性

PIK3CA mutation plays a critical role in the tumorigenesis and resistance of anti-cancer drugs. We evaluated whether PIK3CA mutation would contribute to resistance of docetaxel or tamoxifen in this study. First, we analyzed association between PIK3CA mutation and efficacy of docetaxel in patients who received neoadjuvant docetaxel chemotherapy, but PIK3CA mutation was not associated with sensitivity to docetaxel. Next, we sought to examine interaction between PIK3CA mutation and breast cancer outcomes in patients who are treated with adjuvant tamoxifen alone. In our homogenous dataset of patients treated with tamoxifen alone, the incidence of PIK3CA mutation was 34.1% as consistent to previous studies. Exon9 PIK3CA mutation had a trend to favorable prognosis, in contrast with Exon20 PIK3CA wild type. These two hot spot sites could be different prognostic factor. This may help stratify patients likely to benefit endocrine therapy alone, but our dataset is too small to conclude. Therefore, further studies are needed to confirm this association.

PIK3CA突变在肿瘤发生和抗癌药物耐药中发挥着关键作用。在本研究中，我们评估了 PIK3CA 突变是否会导致多西紫杉醇或他莫昔芬耐药。首先，我们分析了接受新辅助多西紫杉醇化疗的患者中PIK3CA突变与多西紫杉醇疗效之间的关联，但PIK3CA突变与多西紫杉醇敏感性无关。接下来，我们试图检查 PIK3CA 突变与单独接受他莫昔芬辅助治疗的患者的乳腺癌结局之间的相互作用。在我们仅接受他莫昔芬治疗的患者的同质数据集中，PIK3CA 突变的发生率为 34.1%，与之前的研究一致。与 Exon20 PIK3CA 野生型相比，Exon9 PIK3CA 突变具有良好的预后趋势。这两个热点位点可能是不同的预后因素。这可能有助于对可能仅受益于内分泌治疗的患者进行分层，但我们的数据集太小，无法得出结论。因此，需要进一步的研究来证实这种关联。

项目成果

Breast Cancer with PIK3CA Mutations Associated with a Favorable Prognosis in Patients Treated with Tamoxifen Alone

具有 PIK3CA 突变的乳腺癌与单独接受他莫昔芬治疗的患者的良好预后相关

• 发表时间: 2012
• 作者: Fumikata Hara;Sachiko Kiyoto;Mina Takahashi;Daisuke Takabatake;Seiki Takashima;Kenjiro Aogi;Shozo Ohsumi
• 通讯作者: Shozo Ohsumi

ドセタキセル単剤術前化学療法を施行された乳癌患者におけるPIK3CA変異と治療効果の関係

PIK3CA突变与乳腺癌单药多西紫杉醇新辅助化疗疗效的关系

• 发表时间: 2011
• 作者: 原文堅;清藤佐知子;高橋三奈;高畠大典;高嶋成輝;青儀健二郎;大住省三
• 通讯作者: 大住省三

特記事項なし

没有特别说明